References

1. Haffner SM, Miettinen H, Gaskill SP, Stern MP. Decreased insulin action and insulin secretion predict the development of impaired tolerance. Diabetologia 1996; 39:1201-7.

2. Tripathy D, Carlsson M, Almgren P, et al. Insulin secretion and insulin sensitivity in relation to glucose tolerance. Lessons from the Bothnia study. Diabetes 2000; 49:975-80.

3. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 2001; 44:929-45.

4. Gerich JE. Is insulin resistance the principal cause of type II diabetes? Diabet Obes Metab 1999; 1:257-63.

5. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylur-eas or insulin compared with conventional treatment and risk of complications in patients with type II diabetes (UKPDS 33). Lancet 1998; 352:837-53.

6. Smidt N, Barzilay J, Shaffer D, et al. Fasting and 2-hour postchallenge serum glucose measures and risk of incident cardiovascular events in the elderly. The Cardiovascular Health Study. Arch Intern Med 2002; 162:209-16.

7. de Vegt F, Dekker JM, Ruhe HG, et al. Hyperglycaemia is associated with all cause and cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 1999; 42:926-31.

8. Hanefeld M, Schmechel H, Schwanebeck U, Lindner J. [The DIS-Group]. Predictors of coronary heart disease and death in NIDDM: the Diabetes Intervention Study experience. Diabetologia 1997; 40:123-4.

9. DECODE Study group on behalf of the European Diabetes Epidemiology Study Group. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria. Lancet 1999; 354:617-21.

10. Leiter LA, Ceriello A, Davidson JA, et al. International Prandial Glucose Regulation (PGR) Study Group. Postprandial glucose regulation: new data and new implications. Clin Ther 2005; 27(Suppl. 2): S42-56.

11. Temelkova-Kurktschiev T, Koehler C, Henkel E, Hanefeld M. Leukocyte count and fibrinogen are associated with carotid and femoral intima-media thickness in a risk population for diabetes. Cardiovasc Res 2002; 56:277-83.

12. Goke B, Herrmann C, Goke R, et al. Intestinal effects of alpha-glucosidase inhibitors: absorption of nutrients and enterohormonal changes. Eur J Clin Invest 1994; 24(Suppl. 3):25-30.

13. Schmidt DD, Frommer W, Junge B, et al. Alpha-glucosidase inhibitors. New complex oligosaccharides of microbial origin. Naturwissenschaften 1977; 64:535-6.

14. Puls W, Keup U, Krause HP, et al. Glucosidase inhibition. A new approach to the treatment of diabetes, obesity and hyperlipoproteinemia. Naturwissenschaften 1977; 64:536-7.

15. Puls W. Pharmacology of glucosidase inhibitors Oral Antidiabet 1996; 119:497-525.

16. Krause HP, Ahr HJ. Pharmacokinetics and metabolism of glucosidase inhibitors. In: Kuhlmann J, Puls W, eds. Handbook of Experimental Pharmacology: Oral Antidiabetics, vol. 119. Berlin: Springer, 1996:541-5.

17. Taylor R, Bardolph E. Clinical evaluation of glucosidase inhibitors. Oral Antidiabet 1996; 119: 633-46.

18. Junge B, Matzke M, Stoltefuss J. Chemistry and structure-activity relationships of glucosidase inhibitors. In: Kuhlmann J, Puls W, eds. Handbook of Experimental Pharmacology: Oral Antidiabetics, vol. 119. Berlin: Springer, 1996:541-5.

19. Joubert PH, Venter HL, Foukaridis GN. The effect of miglitol and acarbose after an oral glucose load: a novel hypoglycaemic mechanism. Br J Clin Pharmacol 1990; 30:391-6.

20. Caspary WF. Sucrose malabsorption in men after ingestion of alpha-glucosidase hydrolase inhibitor. Lancet 1978; i:1231-3.

21. Holt RR, Atillasoy E, Lindenbaum J, et al. Effects of acarbose on fecal nutrients, colonic pH, and short chain fatty acids and rectal proliferative indices. Metabolism 1996; 45:1179-87.

22. Toeller M. Modulation of intestinal glucose absorption: postponement of glucose absorption by alpha-glucosidase inhibitors. In: Mogensen CE, Standl E, eds. Pharmacology of Diabetes. Berlin: De Gruyter, 1991:93-112.

23. May C. Efficacy and tolerability of step wise increasing dosage of acarbose in patients with non-insulin-dependent diabetes (NIDDM) treated with sulfonylureas. Diabetes Stoffwechsel 1995; 4:3-7.

24. Caspary WF, Lembke B, Creutzfeldt W. Inhibition of human intestinal alpha-glucoside hydrolase activity by acarbose and clinical consequences. In: Creutzfeldt W, ed. Proceedings First International Symposium on Acarbose, Montreux, October 1981. Amsterdam: Excerpta Medica, 1981:27-37.

25. Chiasson JL, Josse RG, Gomis R, et al. For the STOP-NIDDM trial research group. Acarbose can prevent the progression of impaired glucose tolerance to type 2 diabetes mellitus: the STOP-NIDDM trial. Lancet 2002; 359:2072-7.

26. Mertes G. Safety and efficacy of acarbose in the treatment of type 2 diabetes: data from 5-year surveillance study. Diabetes Res Clin Pract 2001; 2:193-204.

27. Chiasson JL, Josse RG, Leiter LA, et al. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabetes Care 1996; 19:1190-3.

28. Laube H, Linn T, Heyen P. The effects of acarbose on insulin sensitivity and proinsulin in overweight subjects with impaired glucose tolerance. Exp Clin Endocrinol Diabetes 1998; 106:231-3.

29. Shinozaki K, Suzuki M, Ikebuchi M, et al. Improvement of insulin sensitivity and dyslipidemia with a new alpha-glucosidase inhibitor, voglibose, in non-diabetic hyperinsulinemic subjects. Metabolism 1996; 45:731-7.

30. Schnack C, Prager RJF, Winkler J, et al. Effect of 8 week a-glucosidase inhibition on metabolic control, C-peptide secretion, hepatic glucose output and peripheral insulin sensitivity in poorly controlled type 2 diabetic patients. Diabetes Care 1989; 12:537-43.

31. Calle-Pascal A, Garcia-Honduvilla J, Martin Alvarez PJ, et al. Influence of 16-week monotherapy with acarbose on cardiovascular risk factors in obese subjects with non-insulin-dependent diabetes mellitus: a controlled, double-blind comparison study with placebo. Diabetes Metab 1996; 22:201-2.

32. Meneilly G, Ryan EA, Radziuk J, et al. Effect of acarbose on insulin sensitivity in elderly patients with diabetes. Diabetes Care 2000; 23:1162-7.

33. Hillebrand I, Boehme K, Frank G, et al. Effects of the glycoside hydrolase inhibitor (BAY g 5421) on post-prandial blood glucose, serum insulin and triglycerides levels in man. In: Creutzfeldt, ed. Frontiers of Hormone Research: The Entero-Insular Axis. Basel: Karger, 1979; 7:290-1.

34. Hanefeld M, Fischer S, Schulze, et al. Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone. Diabetes Care 1991; 14:732-7.

35. Hanefeld M, Haffner SM, Menschikowski M, et al. Different effects of acarbose and glibenclamide on proinsulin and insulin profiles in people with type 2 diabetes. Diabetes Res Clin Pract 2002; 55:221-7.

36. Leboritz HE. A-glucosidase inhibitors as agents in the treatment of diabetes. Diabetes Rev 1998; 6: 132-45.

37. Qualmann C, Nauck MA, Hoist JJ, et al. Glucagon-like peptide 1 (GLP-1) [17-36 amide] secretion in response to luminal sucrose from the upper and lower gut: a study using a-glucosidase inhibition (acarbose). Scand J Gastroenterol 1995; 30:892-6.

38. Goke B, Fuder H, Wieckhorst G, et al. Voglibose is an efficient alpha-glucosidase inhibitor and mobilize the endogenous GLP-1 reserve. Digestion 1995; 56:493-501.

39. Goke B, Herrmann C, Goke R, et al. Intestinal effects of alpha-glucosidase inhibitors: absorption of nutrients and enterohormonal changes. Fur Clin Invest 1994; 24(Suppl. 3):25-30.

40. Holman RR, Turner RC, Cull CA, et al. A randomised double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 1999; 22:960-4.

41. Wolever TMS, Chiasson JL, Josse RG, et al. Small weight loss on long-term acarbose therapy with no change in dietary pattern or nutrient intake of individuals with non-insulin-dependent diabetes. Int J Obes Relat Metab Disord 1997; 21:756-63.

42. Leonardt W, Hanefeld M, Fischer S, et al. Beneficial effects on serum lipids in noninsulin-dependent diabetics by acarbose treatment. Arzt Forschung 1991; 41:735-8.

43. Shinoda Y, Inoue I, Nakano T, et al. Acarbose improves fibrinolytic activity in patients with impaired glucose tolerance. Metabolism 2006; 55:935-9.

44. Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25:10-6.

45. Johnston PS, Feig PU, Coniff RF, et al. Chronic treatment of African-American type 2 diabetes patients with type 2 diabetic patients with alpha-glucosidase inhibition. Diabetes Care 1998; 21:416-21.

46. Rachmani R, Bar-Dayan Y, Ronen Z, Levi Z, Slavachevsky I, Ravid M. The effect of acarbose on insulin resistance in obese hypertensive subjects with normal glucose tolerance: a randomized controlled study. Diabetes Obes Metab 2004; 6:63-8.

47. Coniff RF, Shapiro JA, Robbins D, et al. Reduction in glycosylated hemoglobin and postprandial hyperglycemia by acarbose in patients with NIDDM: a placebo-controlled dose comparison study. Diabetes Care 1995; 18:817-24.

48. Fischer S, Hanefeld M, Spengler M, et al. European study on dose-response relationship of acarbose as a first-line drug in non-insulin-dependent diabetes mellitus: efficacy and safety of low and high doses. Acta Diabetol 1998; 35:34-40.

49. Rybka J, Goke B, Sissmann. European comparative study of 2 a-glucosidase inhibitors, miglitol and acarbose [abstract]. Diabetes 1999; 44(Suppl. 1):101.

50. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin or placebo in dietary-treated NIDDM patients: the Essen II Study. Am J Med 1997; 103:483-90.

51. Hoffmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen study. Diabetes Care 1994; 17:561-6.

52. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter, placebo-controlled trial comparing acarbose with placebo, tolbutamide and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1998; 98:443-51.

53. Hofmann J, Spengler M. Efficacy of 24-week monotherapy with acarbose, metformin, or placebo in dietary-treated NIDDM patients: the Essen-II-Study. Am J Med; 103:483-90.

54. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus: a multicenter controlled clinical trial. Ann Intern Med 1994; 121:928-35.

55. Chiasson JL, Naditch L and The Miglitol Canadian University Investigator Group. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes. Diabetes Care 2001; 24:989-94.

56. Hanefeld M, Bar K. Effizienz und Sicherheit der Kombinationsbehandlung von IT type 2-Diabetikern mit Acarbose und Metformin. Diabetes Stoff 1998; 7:186-90.

57. Rosak C, Hofmann U, Paulwitz O. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application. Diabetes Nutr Metab 2004; 17:137-42.

58. Kelley DE, Schimel D, Bidot P, et al. Efficacy and safety of acarbose in insulin-treated patients with type 2 diabetes. Diabetes Care 1998; 21:2056-61.

59. Dimitriadis G, Hatziagellki E, Alexopoulos E, et al. Effects of a-glucosidase inhibition on meal glucose-tolerance and timing of insulin administration in patients with type I diabetes mellitus. Diabetes Care 1991; 14:393-8.

60. Hollander P, Pi-Sunyer X, Coniff RF. Acarbose in the treatment of type 1 diabetes. Diabetes Care 1997; 20:248-53.

61. Ceriello A, Taboga C, Tonutti L, et al. Post-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996; 39:469-73.

62. Schafer A, Widder J, Eigenthaler M, Bischoff H, Ertl G, Bauersachs J. Increased platelet activation in young Zucker rats with impaired glucose tolerance is improved by acarbose. Thromb Haemost 2004; 92:97-103.

63. Frantz S, Calvillo L, Tillmanns J, et al. Repetitive postprandial hyperglycemia increases cardiac ischemia/reperfusion injury: prevention by the alpha-glucosidase inhibitor acarbose. FASEB J 2005; 19:591-3.

64. Wascher TC, Schmoelzer I, Wiegratz A, et al. Reduction of postchallenge hyperglycaemia prevents acute endothelial dysfunction in subjects with impaired glucose tolerance. Eur J Clin Invest 2005; 35: 551-7.

65. Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290:486-94.

66. Mertes G. Efficacy and safety of acarbose in the treatment of type 2 diabetes: data from a 2-year surveillance study. Diab Res Clin Pract 1998; 40:63-70.

67. Hollander PA. Safety profile of acarbose and alpha glucosidase inhibitor. Drugs 1992; 44(Suppl. 3): 47-53.

68. Gentile S, Turco S, Guarino G, et al. Aminotransferase activity and acarbose treatment in patients with type 2 diabetes. Diabetes Care 1999; 22:12-7.

69. Ben-Am H, Krivo N, Nagachandran P, et al. Interaction between digoxin and acarbose. Diabetes Care 1999; 22:860-1.

70. Scheen AJ, Ferreira Alves de Megalheas AC, Salvatore T, et al. Reduction of the acute bioavailability of metformin by the a-glucosidase inhibitor acarbose in normal man. Eur J Clin Invest 1994; 24 (Suppl. 3):50-4.

71. Hanefeld M, Fischer S, Julius U, et al. and the DIS Group. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up. Diabetologia 1996; 39:1577-83.

72. Temelkova-Kurktschiev T, Kohler C, Henkel E, et al. Post-challenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000; 23:1830-4.

73. Drent ML. Miglitol as single oral hypoglycemic agent in type 2 diabetes [abstract]. Diabetologia 1994; 37(Suppl. 1):211.

4 Steps To Permanent Weight Loss

4 Steps To Permanent Weight Loss

I can't believe I'm actually writing the book that is going to help you achieve the level of health and fitness that you always dreamed of. Me, little scrawny sickly Darlene that was always last picked in gym class. There's power in a good story here so get this book now.

Get My Free Ebook


Post a comment